Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma

1 Apr 2014

Abstract excerpt

Mammalian target of rapamycin (mTOR) is a kinase protein involved in PI3K/AKT signaling with a central role in the processes of cell growth, survival and angiogenesis. Frequent mutations of this pathway make upstream and downstream components novel targets for tailored therapy design. Two mTOR inhibitors - everolimus and temsirolimus - enable an increase in overall survival (OS) or progression-free survival (PFS)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to PI3K/AKT/mTOR signaling in cancer
Share to Renal and related cancers
Share to Renal cell carcinoma treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25152703
DOI: 10.2174/1574362409666140206222746

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell CarcinomaPMID 25152703Read ↗

Molecular Mechanisms of Drug Resistance in Clear Cell Renal Cell CarcinomaSemantic proximity Read ↗

Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.Semantic proximity Read ↗

Functional and genomic characterization of patient-derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinoma.Semantic proximity Read ↗

Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies.Semantic proximity Read ↗

PTEN loss confers sensitivity to rapalogs in clear cell renal cell carcinoma.Semantic proximity Read ↗

Enhancing mTOR-targeted cancer therapySemantic proximity Read ↗

Genetic variants in the mTOR pathway with renal cancer risk and subtypes in East Indian population.Semantic proximity Read ↗

Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapySemantic proximity Read ↗

Review: Mammalian Target of Rapamycin (mTOR) Pathway Is Critical in Developing Most Renal Cell Tumors.Semantic proximity Read ↗

The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma.Semantic proximity Read ↗

Molecular biology of renal cell carcinoma.Semantic proximity Read ↗

PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.